The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $33.12

Today's change+0.92 +2.86%
Updated December 2 2:20 PM EST. Delayed by at least 15 minutes.
 

Sarepta Therapeutics Inc

Nasdaq: SRPT
Last

(U.S.) $33.12

Today's change+0.92 +2.86%
Updated December 2 2:20 PM EST. Delayed by at least 15 minutes.

Sarepta Therapeutics Inc up sharply

Sarepta Therapeutics Inc is up sharply today, rallying (U.S.)$0.92 or 2.86% to (U.S.)$33.12. Over the last five days, shares have lost 11.18% and are down 14.15% for the last year to date. This security has underperformed the S&P 500 by 16.25% during the last year.

Key company metrics

  • Open(U.S.) $32.50
  • Previous close(U.S.) $32.20
  • High(U.S.) $33.38
  • Low(U.S.) $31.81
  • Bid / Ask(U.S.) $33.09 / (U.S.) $33.11
  • YTD % change-14.15%
  • Volume1,147,446
  • Average volume (10-day)2,155,100
  • Average volume (1-month)2,495,915
  • Average volume (3-month)3,681,286
  • 52-week range(U.S.) $8.00 to (U.S.) $63.73
  • Beta1.91
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$5.27
Updated December 2 2:20 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-19,432.88%

Sarepta Therapeutics Inc has a net profit margin of -19,432.88%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.25%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue0001
Total other revenue--------
Total revenue0001
Gross profit--------
Total cost of revenue--------
Total operating expense57626066
Selling / general / administrative22182124
Research & development34443941
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-57-62-60-64
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-57-62-60-65
Income after tax-57-62-60-65
Income tax, total--------
Net income-57-62-60-65
Total adjustments to net income--------
Net income before extra. items-57-62-60-65
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-57-62-60-65
Inc. avail. to common incl. extra. items-57-62-60-65
Diluted net income-57-62-60-65
Dilution adjustment--------
Diluted weighted average shares48464645
Diluted EPS excluding extraordinary itemsvalue per share-1.18-1.35-1.31-1.44
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-1.18-1.35-1.31-1.44